Jun 21 |
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
|
Jun 21 |
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
|
Jun 19 |
Takeda reports long-term data from Phase III CIDP treatment trial
|
Jun 18 |
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
|
Jun 18 |
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
|
Jun 17 |
Takeda’s epilepsy drug misses the mark in two Phase III trials
|
Jun 17 |
Ovid stock plunges 66% on failed studies for soticlestat
|
Jun 17 |
Takeda drug for rare types of epilepsy misses goal in late-stage trial
|
Jun 17 |
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
|
Jun 14 |
Takeda signs option agreement with Ascentage for CML drug
|